Boulder, Colorado – September 5, 2018 – Bolder BioTechnology, Inc. announced today publication of preclinical studies of BBT-059, a long-acting interleukin -11 (IL-11) analog, in mouse models of the hematopoietic acute radiation syndrome. The studies were performed in collaboration with researchers at the Armed Forces Radiobiology Research Institute (AFRRI), the Uniformed Services University of the Health Sciences in Bethesda, MD. The article, entitled “PEGylated IL-11 (BBT-059): a novel radiation countermeasure for hematopoietic acute radiation syndrome”, was published in the journal Health Physics. The study authors are Vidya P. Kumar, Shukla Biswas, Neel K. Sharma, Sasha Stone, Fialka G. Ward, Leonora Dickson, Christine M. Fam, George N. Cox, and Sanchita P. Ghosh. The study results suggest that BBT-059 may prove useful for preventing development of the hematopoietic acute radiation syndrome when administered either pre- or post-radiation exposure. Post-exposure use would primarily be by people who have been accidently exposed to radiation, while pre-exposure use would primarily be by first responders to a radiological or nuclear event.
The original article was published in Health Physics, volume 115(1), pages 65–76, 2018 and can be accessed electronically at DOI: 10.1097/HP.0000000000000841 or PMID: 29787432.
The work described in the publication was funded by grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (AA112044-001-04000), AFRRI Intramural funding RAB23338, and Bolder BioTechnology. The opinions contained in the publication are the private views of the authors, and are not those of the Armed Forces Radiobiology Research Institute, the Uniformed Services of the University of the Health Sciences, or the Department of Defense.
